Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma

STRATUM 1 - INCLUSION CRITERIA * DIAGNOSIS - Patients with progressive DIPG or H3K27M+ Thalamic DMG , as defined by progressive neurologic abnormalities or worsening neurologic status not explained by causes unrelated to tumor progression (e.g., anticonvulsant or corticosteroid toxicity wean, electrolyte disturbances, sepsis, hyperglycemia, etc.), OR an increase in the bi-dimensional measurement, taking as a reference the smallest disease measurement recorded since diagnosis, OR the appearance of a new tumor lesion since diagnosis. * Please note: patients with a radiographically typical DIPG, defined as a tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons, are eligible without histologic confirmation. * Patients with pontine lesions that do not meet these radiographic criteria will be eligible if there is histologic confirmation of malignant glioma WHO II-IV. * Thalamic Diffuse Midline Glioma patients will be eligible if there is tissue confirmation of the H3K27M mutation by immunohistochemistry or by gene testing performed in a CLIA certified laboratory of the investigator's choice. * AGE - Patients must be ≥ 2 but \< 22 years of age at the time of enrollment. * BSA * Patients must have a BSA ≥ 0.80 m2 for dose 5mg/m2. * Patients must have a BSA ≥ 0.65 m2 for doses of 10mg/m2 - 22 mg/m2. * Patients must have a BSA ≥ 0.50 m2 for doses of 28 mg/m2 - 36 mg/m2. * ABILITY TO SWALLOW - Patient must be able to swallow capsules whole. …